The Role of General Practitioners in Prescribing Prostate-Specific Antigen Testing for Early Detection and Treatment of Benign Prostate Hyperplasia

Dimitar Kalinov

doi:10.3889/oamjms.2022.10369

Authors

Dimitar Kalinov Department of Urology and General Medicine, Plovdiv Medical University, Plovdiv, Bulgaria

DOI:

https://doi.org/10.3889/oamjms.2022.10369

Keywords:

Benign prostatic hyperplasia, Prostate-specific antigen, Lower urinary tract symptoms, General practitioner

Abstract

BACKGROUND: Benign prostatic hyperplasia and its clinical manifestation as lower urinary tract symptoms are a major health problem for men over 50 years of age.

AIM: This article aims to demonstrate that general practitioners are in a better position to use prostate-specific antigen testing for identifying men with lower urinary tract symptoms as well as those at risk of disease progression.

METHODS: Thus, they can play a key role in the early detection and diagnosis, as well as in the treatment of men with mild-to-moderate lower urinary tract symptoms who have no evidence of prostate cancer.

RESULTS: The results of studies conducted worldwide show that general practitioners can provide treatment when the intervention of a specialist urologist is not necessary or, guided by their knowledge and clinical judgment, refers the patient to a urologist when the patient’s condition warrants it. In this regard, we suggest that primary care for patients with benign prostatic hyperplasia should provide measures for prevention, diagnosis, treatment, and formation of a healthy lifestyle in patients with this type of pathology.

CONCLUSION: This type of medical care can and should be provided by the general practitioner in the primary care setting.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Roehrborn CG. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and nature history. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, Novick AC, editors. Wein: Campbell-Walsh Urology. 10th ed. Philadelphia, PA: Saunders; 2011a. p. 2570-160.e10.

Naslund MJ, Costa FJ, Miner MM. Managing enlarged prostate in primary care. Int J Clin Pract. 2006;60(12):1609-15. https://doi.org/10.1111/j.1742-1241.2006.01194.x PMid:17109668 DOI: https://doi.org/10.1111/j.1742-1241.2006.01194.x

Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008;77(10):1403-10. PMid:18533373

Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403-15. https://doi.org/10.1016/j.ucl.2009.07.003 PMid:19942041 DOI: https://doi.org/10.1016/j.ucl.2009.07.003

Neal DE, Neal RR, Donovan J. Benign prostatic hyperplasia. In: Stevens A, Raftery J, Mant J, Simpson S, editors. Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews. Ch. 12. Abington: Radcliffe Publishing; 2004. p. 91-158.

Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int. 2008;102(5):536-44. https://doi.org/10.1111/j.1464-410X.2008.07667.x PMid:18410432 DOI: https://doi.org/10.1111/j.1464-410X.2008.07667.x

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation sub-committee of the international continence society. The standardisation of terminology of lower urinary tract function: Report from the standardisation subcommittee of the international continence society. Neurourol Urodyn. 2002;21(12):167-78. https://doi.org/10.1002/nau.10052 PMid:11857671 DOI: https://doi.org/10.1002/nau.10052

Levy A, Samraj GP. Benign prostatic hyperplasia: When to watch and wait,’ when and how to treat. Cleve Clin J Med. 2007;74(Suppl 3):S15-20. https://doi.org/10.3949/ccjm.74.suppl_3.s15 PMid:17546829 DOI: https://doi.org/10.3949/ccjm.74.Suppl_3.S15

Levitt JM, Slawin KM. Prostate-specific antigen and prostatespecific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Urol Rep. 2007;8(4):269-74. https://doi.org/10.1007/s11934-007-0072-y PMid:18519010 DOI: https://doi.org/10.1007/s11934-007-0072-y

American Urological Association. Practice Guideline Committee AUA Guideline on Management of Benign Prostatic Hyperplasia. Linthicum: American Urological Association; 2003. Available from: https://www.auanet.org/content/guidelines-andquality-care/clinical-guidelines.cfm?sub=bph [Last accessed on 2008 Oct 16].

Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: The new paradigm. Can J Urol. 2008;15(Suppl 1):21-30;discussion 30. PMid:18700062

Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol. 2000;163(1):13-20. PMid:10604304 DOI: https://doi.org/10.1016/S0022-5347(05)67962-1

Davidson JH, Chutka DS. Benign prostatic hyperplasia: Treat or wait? J Fam Pract. 2008;57(7):454-63. PMid:18625168

Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology. 1999;53(6):1090-18. https://doi.org/10.1016/s0090-4295(99)00041-2 PMid:10367833 DOI: https://doi.org/10.1016/S0090-4295(99)00041-2

Fowler FJ Jr, Wennberg JE, Timothy RP, Barry MJ, Hanley D, Mulley AG Jr. Symptom status and quality of life following prostatectomy. JAMA. 1988;259(20):3018-22. PMid:2452905 DOI: https://doi.org/10.1001/jama.259.20.3018

Lukacs B, Comet D, Grange JC, Thibault P. Construction and validation of a short-form benign prostatic hypertrophy healthrelated quality-of-life questionnaire. Br J Urol. 1997;80(5):722-30. https://doi.org/10.1046/j.1464-410x.1997.00438.x PMid 9393292 DOI: https://doi.org/10.1046/j.1464-410X.1997.00438.x

Chevalier J, de Pouvourville G. Valuing EQ-5D using time tradeoff in France. Eur J Health Econ. 2013;14:57-66. DOI: https://doi.org/10.1007/s10198-011-0351-x

Weiss J, Andersson F, Juul KV. Diagnosing Nocturnal Polyuria (NP)-Based on Self-Reported Nocturnal Void Volume and Fluid Intake in Clinical Practice: Results from a Real-World Treatment Survey in Europe and the USA. Munch, EAU16, abstract 536. DOI: https://doi.org/10.1016/S1569-9056(16)60538-9

Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol. 2006;16(1):5-10. https://doi.org/10.1097/01.mou.0000193365.46081.cd PMid:16385194 DOI: https://doi.org/10.1097/01.mou.0000193365.46081.cd

Russo GI, Castelli T, Urzi D, Privitera S, La Vignera S, Condorelli RA, et al. Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. Int J Urol. 2015;22(11):982-90. https://doi.org/10.1111/iju.12877 PMid:26193757 DOI: https://doi.org/10.1111/iju.12877

Pinto JD, Hong-Gu HE, Chan SW, Wang W. National University Hospital, Alice Lee Center for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore and School of Nursing and Midwifery, Faculty of Health and Medicine, The University of Newcastle, Newcastle, New South Wales, Australia; 2016.

Browne CT, Emberton M. Self-management for men with lower urinary tract symptoms. Curr Urol Rep. 2009;10(4):261-6. https://doi.org/10.1007/s11934-009-0043-6 PMid:19570486 DOI: https://doi.org/10.1007/s11934-009-0043-6

Doykov M. Treatment of Benign Prostatic Hyperplasia. Vol. 24. Plovdiv: Scientific Papers of the Union of Scientists in Bulgaria-Plovdiv; 2020. p. 154-160.

Doykov M. Catheter-Associated Urinary Tract Infection. Vol. 26. Plovdiv: Scientific Papers of the Union of Scientists in Bulgaria-Plovdiv; 2021. p. 98-102.

Kalinov D, Goranov T, Chitalov J, Dechev I, Despotova-Toleva L. Benign Prostatic Hyperplasia in the Life of Men. The Role of the GP. Bulgaria: Department of Urology and General Medicine, Medical University of Plovdiv; 2021.

Wei JT, Miner MM, Steers WD, Rosen RC, Seftel AD, Pasta DJ, et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol. 2011;186(3):971-6. https://doi.org/10.1016/j.juro.2011.04.081 PMid:21791352 DOI: https://doi.org/10.1016/j.juro.2011.04.081

Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: Evaluation and medical management in primary care. Cleve Clin J Med. 2017;84(1):53-64. https://doi.org/10.3949/ccjm.84a.16008 PMid:28084985 DOI: https://doi.org/10.3949/ccjm.84a.16008

Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15(12):463. https://doi.org/10.1007/s11934-014-0463-9 PMid:25312251 DOI: https://doi.org/10.1007/s11934-014-0463-9

Hu J, Zhang L, Zou L, Hu M, Fan J, Cai Y, et al. The role of inflammation in benign prostatic hyperplasia development among Han Chinese: A population-based and singleinstitutional analysis. Int J Urol. 2015;22(12):1138-42. https://doi.org/10.1111/iju.12914 PMid:26311564 DOI: https://doi.org/10.1111/iju.12914

Foo KT. Diagnosis and treatment of benign prostate hyperplasia in Asia. Transl Androl Urol. 2015;4(4):478-83. https://doi.org/10.3978/j.issn.2223-4683.2015.08.07 PMid:26816845